Indivior Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key financial metrics, driven by a 21% YoY surge in SUBLOCADE revenue to $253M. Revenue reached $343M, 11.5% above the $307.6M consensus, while Normalized EPS of $1.15 exceeded expectations by 24.8%. The company raised its full-year 2026 revenue guidance to $1.295B–$1.365B and announced a definitive merger agreement with Supernus, signaling a strategic transition into a broader CNS-focused biopharma leader.